Company Overview
Company Type: Private Company
Website: www.diamondthera.com
Number of Employees: -
Year Founded: 2018
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Diamond Therapeutics Inc. develops clinical neuropsychiatric drugs for the neurological disorders. It offers FDA, EMA, and psilocybin-based drugs that deliver rapid therapeutic outcomes and eliminates the side effects and administered to a cohort of patients. The company’s therapeutic drugs treat psychopharmacology and neuropsychiatric conditions in the humans. The company was incorporated in 2018 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Blumstock, Judy 
Founder, CEO & Director
McCutcheon, Grant 
Chief Financial Officer
McDonnell, Michael B.
Chief Medical Officer

Key Board Members
Name
Title
Blumstock, Judy 
Founder, CEO & Director
Sellers, Edward M.
Chairman of Scientific Advisory Board
Boadway, Richard D.
Lead Independent Director
Glue, Paul 
Member of Scientific Advisory Board
Kosten, Thomas R.
Member of Scientific Advisory Board
Moskal, Joseph R.
Member of Scientific Advisory Board
Passie, Torsten 
Member of Scientific Advisory Board
Pekos, Peter 
Director
Tyler, William Jamie
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
100 King Street West Suite 6200 | Toronto, ON | M5X 1B8 | Canada
Phone: 416 258 9110   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
First Avenue Ventures LLC
Apr-04-2023
Unknown
-
Growth
Grey House Partners GP Inc.
-
Unknown
-
-
Negev Capital
-
Unknown
-
-
Noetic Fund
-
Unknown
-
-
Ontario Brain Institute
-
Minority
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-04-2023
Apr-04-2023
Private Placement
Target
Diamond Therapeutics Inc.
First Avenue Ventures LLC Buyer Funds:First Avenue Ventures Life Science Fund I, LP

-
Feb-04-2021
Cancelled
Merger/Acquisition
Buyer
GHP Noetic Science-Psychedelic Pharma Inc. (TSXV:PSYF.P)
Diamond Therapeutics Inc.

39.39
Jan-07-2021
Jan-07-2021
Private Placement
Target
Diamond Therapeutics Inc.


-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-04-2023
Private Placements
Diamond Therapeutics Inc. announced that it has received funding from First Avenue Ventures LLC
Jan-24-2023
Product-Related Announcements
Diamond Therapeutics Inc. Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
Dec-07-2022
Product-Related Announcements
Diamond Therapeutics Inc. Completes Phase I Clinical Study of Low-Dose Psilocybin in Healthy Human Subjects
May-03-2022
Client Announcements
GHP Noetic Science-Psychedelic Pharma Inc. and Diamond Therapeutics Announces Termination of Letter of Intent
May-03-2022
M&A Transaction Cancellations
Diamond Therapeutics Inc. cancelled the acquisition of GHP Noetic Science-Psychedelic Pharma Inc. (TSXV:PSYF.P) in a reverse merger transaction.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Blumstock, Judy 
Founder, CEO & Director
416 258 9110
-

Sellers, Edward M.
Chairman of Scientific Advisory Board
416 258 9110
-

Boadway, Richard D.
Lead Independent Director
416 258 9110
-

Glue, Paul 
Member of Scientific Advisory Board
416 258 9110
-

Kosten, Thomas R.
Member of Scientific Advisory Board
416 258 9110
-

Moskal, Joseph R.
Member of Scientific Advisory Board
416 258 9110
-

Passie, Torsten 
Member of Scientific Advisory Board
416 258 9110
-

Pekos, Peter 
Director
416 258 9110
-

Tyler, William Jamie
Member of Scientific Advisory Board
416 258 9110
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Blumstock, Judy 
Founder, CEO & Director
416 258 9110
-

McCutcheon, Grant 
Chief Financial Officer
416 258 9110
-

McDonnell, Michael B.
Chief Medical Officer
416 258 9110
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
